KCM
BIO icon

Kornitzer Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Kornitzer Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8M Sell
6,126
-1,600
-21% -$454K 0.04% 327
2026
Q1 		$2.15M Buy
7,726
+1,120
+17% +$323K 0.05% 297
2025
Q4 		$2M Sell
6,606
-3,010
-31% -$939K 0.04% 324
2025
Q3 		$2.7M Sell
9,616
-725
-7% -$197K 0.05% 290
2025
Q2 		$2.5M Sell
10,341
-27,933
-73% -$6.6M 0.05% 302
2025
Q1 		$9.32M Sell
38,274
-1,029
-3% -$310K 0.19% 138
2024
Q4 		$12.9M Buy
39,303
+786
+2% +$267K 0.25% 107
2024
Q3 		$12.9M Buy
38,517
+3,564
+10% +$1.13M 0.24% 127
2024
Q2 		$9.55M Buy
34,953
+100
+0.3% +$29.1K 0.18% 163
2024
Q1 		$12.1M Sell
34,853
-1,794
-5% -$590K 0.22% 137
2023
Q4 		$11.8M Sell
36,647
-4,048
-10% -$1.27M 0.23% 132
2023
Q3 		$14.6M Hold
40,695
– – 0.3% 93
2023
Q2 		$15.4M Sell
40,695
-5,000
-11% -$2.03M 0.3% 93
2023
Q1 		$21.9M Buy
45,695
+4,635
+11% +$2.17M 0.44% 54
2022
Q4 		$17.3M Buy
41,060
+16,257
+66% +$6.56M 0.35% 78
2022
Q3 		$10.3M Sell
24,803
-1,107
-4% -$552K 0.22% 154
2022
Q2 		$12.8M Hold
25,910
– – 0.26% 131
2022
Q1 		$14.6M Hold
25,910
– – 0.24% 139
2021
Q4 		$19.6M Hold
25,910
– – 0.29% 116
2021
Q3 		$19.3M Sell
25,910
-630
-2% -$472K 0.3% 120
2021
Q2 		$17.1M Hold
26,540
– – 0.26% 155
2021
Q1 		$15.2M Hold
26,540
– – 0.24% 162
2020
Q4 		$15.5M Sell
26,540
-1,400
-5% -$797K 0.26% 138
2020
Q3 		$14.4M Sell
27,940
-17,585
-39% -$8.91M 0.28% 134
2020
Q2 		$20.6M Sell
45,525
-11,387
-20% -$5.03M 0.41% 76
2020
Q1 		$20M Buy
56,912
+49,422
+660% +$18.2M 0.47% 58
2019
Q4 		$2.77M Sell
7,490
-1,236
-14% -$436K 0.05% 305
2019
Q3 		$2.9M Buy
8,726
+750
+9% +$245K 0.05% 303
2019
Q2 		$2.49M Buy
7,976
+1,990
+33% +$596K 0.04% 313
2019
Q1 		$1.83M Buy
5,986
+1,771
+42% +$478K 0.03% 326
2018
Q4 		$979K Buy
+4,215
New +$1.13M 0.02% 383

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Kornitzer Capital Management's BIO Position: Q2 2026 in Review

Kornitzer Capital Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 21% in Q2 2026, selling an estimated $454K and leaving 6,126 shares worth $1.8M. The position accounts for 0.04% of the portfolio, ranked #327.

Kornitzer Capital Management first reported a position in BIO in Q4 2018 and has held it in 31 quarters since. The position peaked at $21.9M in Q1 2023. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Kornitzer Capital Management held 6,126 shares of Bio-Rad Laboratories Class A worth $1.8M as of Q2 2026.
  • Kornitzer Capital Management sold 1,600 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $454K.
  • Bio-Rad Laboratories Class A made up 0.04% of Kornitzer Capital Management's portfolio in Q2 2026, its #327 holding.
  • Kornitzer Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2018 and has held it in 31 quarters since.
  • Kornitzer Capital Management's Bio-Rad Laboratories Class A position peaked at $21.9M in Q1 2023.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Kornitzer Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.